From causality to prevention - The example of cervical cancer: My personal contribution to this fascinating history

Public Health Genomics

Volumn 12, Issue 5-6, 2009, Pages 368-371

  Muñoz, Nubia ^a,b  

^a National Cancer Institute of Colombia ^*  (France)

^b Instituto Nacional de Cancerología   (Colombia)

Author keywords

Cervical cancer, causation; Cervical cancer, prevention; Cytomegalovirus; Herpes simplex type 2; Human papillomavirus

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; DIAGNOSTIC ACCURACY; HISTORY OF MEDICINE; HUMAN; HYPOTHESIS; MOLECULAR EPIDEMIOLOGY; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS TYPING;

CYTOMEGALOVIRUS; HERPES; HUMAN PAPILLOMAVIRUS;

EID: 69249138747     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214927     Document Type: Article

References (24)

1. Muñoz N: Model systems for cervical cancer. Cancer Res 1976; 36: 792-793.
2. zur Hausen H: Condylomata acuminata and human genital cancer. Cancer Res 1976; 36: 794.
3. Gissmann L, zur Hausen H: Human papillomavirus DNA: physical characterization and genetic heterogeneity. Proc Natl Acad Sci USA 1976; 73: 1310-1313.
4. Durst M, Gissmann L, zur Hausen H: A papillomavirus DNA from a cervical carcinoma and prevalence in cancer biopsy samples from different geographical regions. Proc Natl Acad Sci USA 1983; 80: 3812-3815.
5. Muñoz N, Bosch FX, Kaldor JM: Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. Br J Cancer 1988; 57: 1-5.
6. Muñoz N, Bosch FX, Jensen OM (eds): Human Papillomavirus and Cervical Cancer. IARC Scientific Publication No. 94. Lyon, IARC, 1989.
7. Muñoz N, Bosch FX, Shah KV, Meheus A (eds): The Epidemiology of Cervical Cancer and Human Papillomavirus. IARC Scientific Publication No. 119. Lyon, IARC, 1992.
8. Muñoz N, Bosch FX, de Sanjosé S, et al: The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992; 52: 743-749.
9. Muñoz N, Bosch FX, de Sanjosé S, et al, for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003; 348: 518-527.
10. Muñoz N, Franceschi S, Bosetti C, et al, for the International Agency for Research on Cancer, Multicentric Cervical Cancer Study Group (2002): Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002; 359: 1093-1101.
11. Muñoz N, Castellsagué X, de Gonzalez AB, Gismann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24: 1-10.
12. Muñoz N, Castellsagué X, Bosch FX, Tafur L, de Sanjosé S, Aristizabal N, Ghaffari AM, Shah KV: Difficulty in elucidating the male role in Colombia, a high-risk area for cervical cancer. J Natl Cancer Inst 1996; 88: 1068-1075.
13. Castellsagué X, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, de Sanjosé S, Eluf-Neto J, Ngelangel C, Chichareon S, Smith JS, Herrero R, Franceschi S, for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Male circumcision, penile human papillomavirus infection, and cervical cancer. N Engl J Med 2002; 346: 1105-1112.
14. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJLM, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
15. Muñoz N, Bosch FX, Castellsagué X, Diaz M, de Sanjosé S, Hammouda D, Shah KV, Meijer CJLM: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-285.
16. Ault KA; Future II Study Group: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-1868.
17. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-2170.
18. Villa LL, Costa RLR, Petta CA, et al: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/ 16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459-1466.
19. Muñoz N, Franco EL, Herrero R, Andrus JK, de Quadros CA, Bosch FX: Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008; 26:L96-L107.
20. Cuzick J, Clavel C, Petry KU, Meijer CJLM, Hoyer H, Ratnam S, et al: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-1105.
21. Franco EL, Tsu V, Herrero R, Lazcano-Ponce E, Hildesheim A, Muñoz N, et al: Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine 2008; 26:L88-L95.
22. Goldie SJ, Diaz M, Constela D, Alvis N, Andrus JK, Kim SY: Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008; 26:L59-L72.
23. Qiao YL, Sellors J, Eder PS, et al: A new test for cervical cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929-936.
24. Sankaranayanan R, Nene BM, Shastri SS, et al: HPV screening for cervical cancer in rural India. N Engl J Med 2009;360: 1385-1394.